Compare Campbell Soup Co. (CPB) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Crispr Therapeutics AG — how do they compare? Campbell Soup Co. trades at $19.21 (market cap $5.78B), while Crispr Therapeutics AG trades at $53.39 (market cap $4.88B). The key difference: Campbell Soup Co. is the larger of the two by market cap, and Campbell Soup Co. pays a 5.16% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Crispr Therapeutics AG for 77 Days on average.
| CPB | CRSP | |
|---|---|---|
Market Cap | $5.78B | $4.88B |
Volume | 11,705,427 | 2,861,747 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $73.97 |
52-Week Low | $18.90 | $44.34 |
Typical Hold Time | 98 Days | 77 Days |
Enterprise Value | $12.83B | $3.30B |
Dividend Yield | 5.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $19.37, up 2.49% with bearish technical signals and mixed fundamentals. The company reported a Q4 2026 earnings miss but beat expectations in Q1 and Q2 2026. Recent developments include a 36% dividend cut to $0.25, workforce reductions, and a $500 million cost savings program. Revenue grew to $10.25B in 2025, but net margins compressed to 4.14% amid margin pressure.
Outlook remains challenging with weak FY2027 guidance and declining profitability trends. The stock offers a 5% dividend yield post-cut, but execution risks on cost savings and competitive pressures in the packaged food sector create headwinds. Analyst consensus is cautious with 58.62% Hold ratings and a $19.73 price target near current levels.
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
